Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
112 hedge funds and large institutions have $311M invested in Accelerate Diagnostics in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 28 increasing their positions, 36 reducing their positions, and 19 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
9% less funds holding
Funds holding: 123 → 112 (-11)
22% less repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 36
31% less capital invested
Capital invested by funds: $448M → $311M (-$137M)
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
63% less call options, than puts
Call options by funds: $1.18M | Put options by funds: $3.18M
Top Buyers
| 1 |
CC
Chicago Capital
Chicago,
Illinois
|
+$16.8M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$3.16M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.82M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$1.6M |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$1.25M |
Top Sellers
| 1 |
Morgan Stanley
New York
|
-$4.77M |
| 2 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$4.11M |
| 3 |
SM
Senvest Management
New York
|
-$4M |
| 4 |
Axa
Paris,
France
|
-$3.33M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.6M |
AXDX Hedge Fund Activity: Q3 2020 in Review
112 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q3 2020, worth a combined $311M — down 31% from $448M a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of AXDX and 8 opened new positions — a net loss of 11 holders — while 36 trimmed existing stakes and 28 added.
The largest buyer was Chicago Capital, adding an estimated $16.8M. The largest seller was Morgan Stanley, cutting an estimated $4.77M.
- 112 institutional investors held Accelerate Diagnostics (AXDX) as of Q3 2020, down from 123 in Q2 2020.
- Funds reported $311M of Accelerate Diagnostics stock for Q3 2020, down 31% quarter-over-quarter.
- 8 funds opened new Accelerate Diagnostics positions in Q3 2020 and 19 closed out, a net change of -11 holders.
- The largest Accelerate Diagnostics buyer in Q3 2020 was Chicago Capital, an estimated $16.8M added.
- The largest Accelerate Diagnostics seller in Q3 2020 was Morgan Stanley, an estimated $4.77M sold.
Based on aggregated 13F filings for Q3 2020.